deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT01436864

A Randomized, Double-masked, Multicenter,Sham-controlled, Safety and Efficacy Study of KH902 in Patients With Wet AMD (PHOENIX)

A Phase 3 Clinical Trial of Intravitreal Injections of Human Recombinant Vascular Endothelial Growth Factor Receptor-Fc Fusion Protein in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration

Sponsor: Chengdu Kanghong Biotech Co., Ltd.

Conditions Neovascular Age-related Macular Degeneration
Interventions Recombinant Human VEGF Receptor-Fc Fusion Protein
Updated 7 times since 2017 Last updated: Apr 13, 2023 Started: Aug 31, 2011 Primary completion: Dec 31, 2012 Completion: Nov 30, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01436864, this PHASE3 trial focuses on Neovascular Age-related Macular Degeneration and remains completed. Sponsored by Chengdu Kanghong Biotech Co., Ltd., it has been updated 7 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Feb 2019 · 8 months · monthly snapshotCompleted~Feb 2019 – ~Jan 2021 · 23 months · monthly snapshotCompleted~Jan 2021 – ~May 2023 · 28 months · monthly snapshotCompleted~May 2023 – ~Jul 2024 · 14 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 22 months · monthly snapshotCompleted

Change History

7 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  3. May 2023 — Jul 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — May 2023 [monthly]

    Completed PHASE3

  5. Feb 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Feb 2019 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Aug 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Chengdu Kanghong Biotech Co., Ltd.
  • University of Wisconsin, Madison
Data source: Chengdu Kanghong Biotech Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations